N@N

Robyn Karnauskas Maintained (VRTX) at Strong Buy with Increased Target to $508 on, Jan 31st, 2024

Robyn Karnauskas of Truist Securities, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Strong Buy with Increased Target from $456 to $508 on, Jan 31st, 2024.

Robyn has made no other calls on VRTX in the last 4 months.

There are 9 other peers that have a rating on VRTX. Out of the 9 peers that are also analyzing VRTX, 3 agree with Robyn's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Brian Abrahams of "RBC Capital" Maintained at Hold with Increased Target to $379 on, Thursday, December 14th, 2023
• Paul Matteis of "Stifel" Reiterated at Hold and Held Target at $373 on, Wednesday, November 22nd, 2023
• Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $364 on, Wednesday, November 8th, 2023

These are the ratings of the 6 analyists that currently disagree with Robyn

---

• Olivia Brayer of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $440 on, Wednesday, January 24th, 2024
• Whitney Ijem of "Canaccord Genuity" Downgraded from Hold to Strong Sell and Increased Target to $379 on, Wednesday, January 24th, 2024
• Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $397 on, Monday, December 11th, 2023
• Gena Wang of "Barclays" Maintained at Buy with Increased Target to $415 on, Monday, December 11th, 2023
• Evan Seigerman of "BMO Capital" Maintained at Buy with Increased Target to $415 on, Tuesday, November 7th, 2023
• Eric Schmidt of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $370 on, Tuesday, October 17th, 2023

Contributing Sources

---